Unusual 11 Mid-Day Movers 9/30: (NVFY) (AUPH) (ITUS) Higher; (VEC) (THLD) (DCTH) Lower

September 30, 2016 12:56 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Vectrus, Inc. (NYSE: VEC) 46.1% LOWER; announced the government did not select the company's contract proposal to provide comprehensive support services for all U.S. Army facilities in Kuwait. Vectrus is the incumbent contractor providing these services, under the Kuwait Base Operations & Security Support Services (K-BOSSS) contract which currently runs through Dec. 28, 2016.

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) 42.2% LOWER; announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib and outlined its plans to focus company resources on the more clinically-advanced evofosfamide program as well as an earlier-stage anticancer candidate, TH-3424. The company will make no further investment in the tarloxotinib program.

Nova LifeStyle, Inc. (Nasdaq: NVFY) 38.3% HIGHER; announced it has signed a Share Transfer Agreement (“Agreement”) with Kuka Design Limited, a company incorporated in BVI (“Kuka BVI”) to sell NOVA BVI and its subsidiaries, which consists of the Company’s manufacturing operations in mainland China (the “Transaction”). With the slow-down of the Chinese economy and a significant increase in labor and other costs for manufacturing facilities in China, the Company decided to sell NOVA BVI, allowing the Company to transition to a “light-asset” business model with greater flexibility and scalability while also focusing its operations on designing, developing, branding, marketing and distributing furniture products in North America, Asia and around the world.

Delcath Systems, Inc. (Nasdaq: DCTH) 25.1% LOWER; announced the pricing of an underwritten public offering of 425,000 shares of its common stock at a price of $3.00 per share, for gross proceeds of $1,275,000. Investors will also receive 0.35 warrants to purchase an additional share of common stock at an initial exercise price of $3.00 per share, with a term of five years. The offering is expected to close on October 5, 2016, subject to customary closing conditions.

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) 19.3% HIGHER; announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group.

ITUS Corporation (Nasdaq: ITUS) 15.9% HIGHER; announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Ovarian Cancer. There is currently no sufficiently accurate test for the early detection of Ovarian Cancer, which has a 5-year survival rate of only 46%.

Calamp Corp. (Nasdaq: CAMP) 15.2% LOWER; reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $90.5 million versus the consensus estimate of $92.26 million. Calamp Corp. sees Q3 2017 EPS of $0.24-$0.30, versus the consensus of $0.31.

Deutsche Bank (NYSE: DB) 14.3% HIGHER; Agence France-Press said that the company is near a $5.4 billion settlement with the U.S. over mortgage bonds. Previous reports noted the DoJ was seeking $14 billion.

Lexmark (NYSE: LXK) 13.7% HIGHER; disclosed CFIUS approval for the Apex deal in an U.S. SEC filing on Friday: In connection with the pending acquisition of Lexmark International, Inc., a Delaware corporation (the “Company”), by a consortium of investors led by Apex Technology Co., Ltd. and PAG Asia Capital (the “Consortium”), the parties filed a joint voluntary notice under Section 721 of the Defense Production Act of 1950, as amended (“DPA”), with the Committee on Foreign Investment in the United States (“CFIUS”) that was accepted on July 15, 2016.

Emergent BioSolutions Inc. (NYSE: EBS) 12.9% HIGHER; announced that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced development and delivery of NuThraxTM (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909.

Cognizant (Nasdaq: CTSH) 12.2% LOWER; disclosed the following in a U.S. SEC filing on Friday: The Company is conducting an internal investigation into whether certain payments relating to facilities in India were made improperly and in possible violation of the U.S. Foreign Corrupt Practices Act and other applicable laws. The investigation is being conducted under the oversight of the Audit Committee, with the assistance of outside counsel, and is currently focused on a small number of Company-owned facilities. The Company has voluntarily notified the United States Department of Justice and United States Securities and Exchange Commission and is cooperating fully with both agencies. The internal investigation is in its early stages, and the Company is not able to predict what, if any, action may be taken by the DOJ, SEC or any governmental authority in connection with the investigation or the effect of the matter on the Company’s results of operations, cash flows or financial position.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Deutsche Bank, Unusual 11 Mid-Day Movers, Definitive Agreement

Add Your Comment